About Us

  • Home 
  • > About Us > 
  • About Us


CbsBioscience Inc., the leading company in Prognostic Gene Test for HCC Patient.

The First Prognostic Gene Test for HCC Patient , OncoHepaTest® is developed through an integrated scientific approach that unites molecular biology techniques (BT), cutting-edge medical technology(MT), patented bioinformatics tools and database management(IT), and statistical tools for clinical and experimental data management (ST).

CEO Park,
Jin Young
- Founder of CbsBioscience
- CEO of Bioinformatics Inc.
- Executive Director of Genetica
Director of R & D
Kim, Kun Do
- Ph.D. Biochemistry & Molecular Biology, University of Glasgow, U. K. (1992 ~ 1996)
- Professor in Pukyong National University
- gundokim@cbsbio.com

BIOMEDICAL BIG DATA ANALYSIS

This is the core step for a discovery of potential biomarker candidates . Utilizing a number of tissues derived from cancer patients, biomedical big data including experimental data, clinicopathological data, and bioinformatics data will be integrated by in-house database system and give an accurate diagnostics and drugs for precision medicine

CDx

Based on the biomedical big data, predictive biomarkers foracertain drug ranging from cytotoxic drug to moleculartargeted drug , immunooncology drug, and siRNA therapeutics, can be tested in patients tissues in clinical trials'

CDx-BASED DRUG

Predictive biomarkers indicate whether a drug will be effective in a specific patient. Based on the CDx biomarkers , drugs with off-Iabel or failed to clinical trial could be rescued in a first-in-class or best-in-class.

BIOMEDICAL BIG DATA SOLUTION